Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ponatinib hydrochloride works in treating patients with
stage III-IV lung cancer. Ponatinib hydrochloride may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.